ClearPoint Neuro

ClearPoint Neuro operates in the specialist medical-device and neurotechnology segment, where its core proposition is image-guided stereotactic navigation combined with tools for delivering devices and therapies to targeted brain regions. Its portfolio spans the ClearPoint Navigation System and software, SmartFlow Cannula, SmartFrame OR Platform, Prism Neuro Laser Therapy System, and IRRAflow Active Fluid Exchange System. The breadth links procedural guidance with delivery and related neurosurgical workflows rather than focusing on a single instrument. Established companies such as Medtronic and Elekta are relevant adjacent competitors in neurosurgical and image-guided procedure markets, although the available company information does not establish direct product-by-product comparisons. ClearPoint’s stated differentiation is its navigation-and-delivery platform, including MRI- and CT-guided workflows and an operating-room platform designed to support navigation without requiring an MRI-guided procedure. The company is public (NASDAQ: CLPT), with a reported 101–250 employees and a $198.9 million cumulative funding total. Its 2026 Canadian authorization, EU software certification, and focused-ultrasound collaboration point to efforts to extend the platform’s geographic and therapeutic applications.

ClearPoint Neuro’s trajectory combines a long operating history with a shift toward broader therapy-delivery applications. Founded in 1998 and public since 2020, it has 18 reported funding rounds and $198.9 million in total funding; its latest listed financing is $20 million in post-IPO debt dated November 20, 2025. Other 2025 financings include $30 million in post-IPO debt and approximately $3.5 million in post-IPO equity, with Oberland Capital identified as a lead investor. Product milestones include the full market release of Navigation Software Version 3.0 in April 2025, EU MDR certification for Version 3.0.2 in January 2026, and Canadian authorization in April 2026. The May 2026 10-year focused-ultrasound partnership extends the strategy toward blood-brain barrier drug delivery. Headcount was reported in the 101–250 range, and the company described expanding R&D, clinical, and support teams in 2024. Second-quarter 2026 revenue rose 18% to $10.9 million, but management lowered its full-year revenue outlook to $48–$52 million. That combination suggests continued platform and market expansion, with commercialization and revenue conversion remaining key execution tests.